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Summary
Melanoma is considered to be the most immunogenic malignant tumour. This fact is recognized for many years, and 
certain forms of immunotherapy have been used in melanoma therapy for a considerable time.
Treatment options for patients with metastatic melanoma have changed dramatically in the past 5 years, with the FDA 
approval of eight new therapeutic agents (immunotherapies and targeted therapies). During this period, melanoma immu-
notherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic Tlymphocyte-
associated antigen4 (CTLA4) and, recently, the programmed cell-death protein 1 (PD1) immune checkpoints. These changes 
in the treatment options have dramatically improved patient outcomes, with the median overall survival of patients with 
metastatic melanoma increasing from approximately 9 months before 2011 to at least 2 years, and probably longer.
Various types of immunotherapy, like pembrolizumab, nivolumab, ipilimumab, combined therapy with nivolumab 
and ipilimumab, and T-VEC, have been established in recent years as the standard-of-care treatment for metastatic mela-
noma patients.
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NOVOSTI U IMUNOTERAPIJI MELANOMA
Sažetak
Melanomi se smatraju najimunogenijim zloćudnim tumorima. Ova je činjenica prepoznata već niz godina, te se neki 
oblici imunoterapije već dugo primjenjuju u liječenju melanoma.
Terapijske opcije za liječenje bolesnika s metastatskim melanomom dramatično su se promijenile u zadnjih pet godina, 
te je Američka agencija za lijekove (FDA) odobrila osam novih lijekova (imunoterapije i ciljane terapije). Tijekom ovog 
 razdoblja, imunoterapija melanoma promijenila se iz terapije bazirane na citokinima u protutijelima posredovanu blokadu 
citotoksičnog T-limfocitnog antigena 4 (CTLA-4), a u zadnje vrijeme u protutijelima posredovanu inhibiciju imunoloških 
kontrolnih točaka, prvenstveno proteina programirane stanične smrti 1 (PD-1). Ove su promjene terapijskih opcija drama-
tično poboljšale ishod liječenja bolesnika, te se medijan ukupnog preživljenja kod bolesnika s metastatskim melanomom 
povisio s približno 9 mjeseci prije 2011. godine, na najmanje 2 godine, a vjerojatno i dulje. Različiti oblici imunoterapije, 
poput pembrolizumaba, nivolumaba, ipilimumaba, kombinirane terapije nivolumabom i ipilimumabom, te T-VEC, postali 
su zadnjih godina standardni oblici liječenja bolesnika s metastatskim melanomom.
KLJUČNE RIJEČI: imunoterapija, melanom, inhibitori imunoloških kontrolnih točaka, onkolitičke vakcine
INTRODUCTION
Melanoma is considered to be the most im-
munogenic malignant tumour with the highest 
prevalence of somatic mutations (1). This fact is 
recognized for many years, and certain forms of 
immunotherapy have been used in melanoma 
therapy for a considerable amount of time.
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Melanoma, particularly cutaneous melano-
ma, is amendable to immunotherapy for various 
reasons, including extensive tumour infi ltration 
by T cells, a high mutational load, and crosstalk 
between oncogenic signalling pathways and im-
munobiology.
Treatment options for advanced-stage, unre-
sectable or metastatic melanoma has changed dra-
matically over a short period of time. Before 2011, 
metastatic melanoma was considered a disease al-
most uniformly fatal within 18 months of diagno-
sis. Standard-of-care treatments during this time 
included limited chemotherapy options, some-
times in conjunction with interferon-alpha (IFN-al-
pha) but with no substantial added benefi t, and in 
highly selected patients, immunotherapy with the 
cytokine interleukin-2 (IL-2) was applied (2).
The median overall survival of patients was 
roughly 9 months, and no treatment had been 
demonstrated to improve survival in a random-
ized phase 3 trial. Since then, due to advances in 
basic research and bett er understanding of ge-
nomic and immune responses against cancer, 
eight new melanoma therapies have been ap-
proved by FDA and EMA, from the fi eld of immu-
notherapy and targeted therapy, rapidly changing 
the therapeutic landscape in metastatic melanoma 
patients. This transferred to, until now, unprece-
dented improvement in overall survival of meta-
static melanoma patients, changing the therapeu-
tic goals from palliative delay in disease progres-
sion in few patients, to durable clinical responses 
for a substantial patients’ number, and eff ective 
disease control and palliation in the majority.
In addition, most patients who nowadays de-
velop metastatic disease following a diagnosis of 
high-risk primary or regionally advanced melano-
ma have the possibility of surviving for years, ow-
ing to the availability of eff ective treatment options.
Immunotherapy has also achieved advances 
in adjuvant melanoma treatment, with the neoad-
juvant treatment options currently under investi-
gation.
Immunotherapy in metastatic melanoma 
treatment
High dose interleukin-2 has shown to be the 
fi rst effi  cient systemic immunotherapy in meta-
static/advanced melanoma, and in USA has been 
used for many years in highly selective patients, 
leading to even long term survival, but at a cost of 
extremely high, often life threatening toxicity (3). 
Other cytokines have been studied in advanced 
melanoma patients as well. Interferon-alpha ther-
apy had limited effi  ciency in metastatic disease, 
but had been used combined with chemotherapy 
(so called biochemotherapy). However, interfer-
on-alpha has a certain role in adjuvant treatment 
of high-risk melanomas (4). Diff erent melanoma-
specifi c vaccines can comprise of specifi c antigens, 
whole melanoma cells, or melanoma cells lyzates, 
and have been investigated both in adjuvant ther-
apy, and in treatment of metastatic disease.
CHECKPOINT INHIBITORS
CTLA-4 inhibitors
Turning point in melanoma immunotherapy 
has arrived in 2011 with ipilimumab, monoclonal 
antibody directed against cytotoxic Tlymphocyte-
associated antigen4 (CTLA4), as the fi rst represen-
tative of modern immunotherapy options. Two 
randomized phase 3 studies have shown pro-
longed overall survival (OS) with ipilimumab in 
metastatic melanoma with plateau of survival 
curve over three years (5,6). However, new immu-
nomodulatory drugs have emerged, more effi  cient 
and less toxic, directed against programmed cell-
death protein 1 (PD1). Today, based on results of 
study CA184-002, ipilimumab monotherapy 
(where available) is considered valid second line 
immunotherapy option after failure of more effi  -
cient types of immunotherapy. The 3 mg/kg dose 
is considered the “standard” dose of ipilimumab, 
however, there has continued to be debate in the 
fi eld about the most appropriate dose of ipilim-
umab, and clinical trials have continued to inves-
tigate the 10 mg/kg dose.
The use of ipilimumab has provided clini-
cans with experience regarding specifi c features of 
immunotherapy – longer period to therapeutic re-
sponse (often several months after the beginning 
of therapy), duration of therapeutic response 
months after cessation of therapy with the possi-
bility for long-term responses, even complete re-
sponses, the potential of partial responses to turn 
into complete responses with longer follow-up, 
immune-related side eff ects (endocrinopathies, 
pneumonitis, collitis, hepatitis, nephritis, derma-
tologic side eff ects…) demanding specifi c treat-
ment, possible pseudoprogression i.e. transient 
worsening of the disease (progression of existing 
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or/and emerging of new metastatic lesions) with 
the need for diff erent validation of tumour re-
sponse to treatment using so called immune-relat-
ed response criteria – irRC.
PD-1 inhibitors
Shortly after ipilimumab, programmed cell-
death protein 1 inhibitors, or anti-PD-1, namely 
pembrolizumab and nivolumab, have appeared 
in the treatment of metastatic melanoma. These 
drugs have been shown to be more effi  cient than 
ipilimumab, with lower toxicity.
It is important to emphasize that immuno-
therapy can be used in metastatic melanoma pa-
tients regardless of BRAF V600 status (whereas 
BRAF V600 – positivity is the prerequisite for tar-
geted therapies), and regardless of programmed-
death ligand 1 (PD-L1) expression (unlike immu-
notherapy based on checkpoint inhibition in some 
other malignant diseases, i.e. lung cancer). Name-
ly, although patients with higher expression levels 
of PD-L1 have higher response rates (RR) to im-
munotherapy, longer progression free survival 
(PFS), and longer overall survival, there is still suf-
fi cient benefi t (sometimes with even long-term re-
sponse) in the treatment of metastatic melanoma 
patients with low expression levels of PD-L1 to 
treat them with immunotherapy.
Pivotal clinical studies for pembrolizumab 
in metastatic melanoma treatment are Keynote 
(KN) 001 (7), KN-002 (8), and KN-006 (9, 10). In 
KN-001 study, overall response rate (ORR) was 
33%, with median OS 24 months, OS rates of 73% 
after 12 months, 50% after 24 months, and 40% af-
ter 36 months of follow-up, respectively.
In registration study Keynote-006, pembroli-
zumab has shown to be more effi  cient than ipilim-
umab, with bett er objective RR (36% vs 13%), bet-
ter PFS (in three-weekly regimen - 38% vs 19% af-
ter 12 months, 28% vs 14% after 24 months, 
HR=0.61), bett er OS (68% vs 59% after 12 months, 
55% vs 43% after 24 months of follow-up, respec-
tively, HR=0.68), and lower toxicity.
Pivotal clinical studies for nivolumab in met-
astatic melanoma treatment are CheckMate (CM) 
-037 (11) and -066 (12). In the phase 1 study with 
the longest follow-up of nivolumab treatment in 
metastatic melanoma, ORR was 32%, median 
overall survival was 17 months, and OS rates were 
63% (after 1-year of follow-up), 48% (after 2 years), 
42% (after 3 years), 35% (after 4 years), and 34% 
(after 5 years of follow-up), respectively.
In CheckMate-066, treatment naïve patients 
(i.e. previously untreated), have received either 
nivolumab or standard chemotherapy protocole 
with dacarbazine. Patients receiving nivolumab 
had signifi cantly higher OS rates (73% vs 42%, HR 
for death 0.42), signifi cantly higher median PFS 
(5.1 months vs 2.2 months), and signifi cantly high-
er ORR (40% vs 14%).
Combined immunotherapy (CTLA-4 inhibitors 
and anti-PD-1 inhibitors)
Combined use of anti-CTLA-4 antibody ipil-
imumab and anti-PD-1 antibody nivolumab has 
higher effi  cacy in metastatic melanoma treatment 
compared to monotherapy with either drug, but 
at the cost of high(er) toxicity.
The largest study exploring this combination 
in metastatic melanoma treatment was double 
blind, placebo controlled phase 3 study – Check-
Mate-067 (13,14) with 945 therapy naïve patients 
randomized to receive either nivolumab and ipili-
mumab for three cycles, followed by nivolumab 
only, or nivolumab monotherapy, or ipilimumab 
monotherapy (latt er for only 4 cycles). Objective 
response rates were 58% for combination therapy 
(with 12.1% of complete responses /CR/), 44% for 
nivolumab monotherapy (with 9.8% CR), and 19% 
for ipilimumab monotherapy (with 2.2% CR). Me-
dian PFS in combination therapy was 11.5 months, 
compared to 6.9 months using nivolumab mono-
therapy (HR=0.55), and 2.9 months using ipilim-
umab monotherapy (HR=0.42). PFS rates after 18 
months of therapy were 46% for combination, 39% 
for nivolumab, and 14% for ipilimumab. Recent 
results showed the fi rst OS data for CM-067. With 
a minimum follow-up of 28 months, the median 
OS had not yet been reached in either of the two 
nivolumab treatment groups and was 20 months 
for the ipilimumab monotherapy group. Nivo-
lumab in combination with ipilimumab and as a 
monotherapy reduced the risk of death 45% (HR 
0.55; P<0.0001) and 37% (HR 0.63; P<0.0001), re-
spectively, compared with ipilimumab alone. The 
two-year OS rates were 64% for the nivolumab 
plus ipilimumab combination, 59% for nivolumab 
alone and 45% for ipilimumab alone. Severe toxic-
ity and the need for discontinuation of treatment 
were more frequent in combination arm compared 
to both monotherapy arms, with 55% of adverse 
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eff ects of grade 3 and 4 in combination therapy vs 
16% in nivolumab group, and 27% in ipilimumab 
group.
Despite expectations, sequential use of 
nivolumab and ipilimumab showed similar toxic-
ity (as well as similar effi  cacy), as concomitant i.e. 
combined use of both drugs. Consequently, it 
does not provide any benefi t over combined use.
Just recently, results from two clinical trials 
presented at ASCO 2017, CheckMate-204 trial (15), 
and Anti-PD-1 Brain Collaboration (ABC) trial 
(16), showed that combination checkpoint inhibi-
tors (nivolumab and ipilimumab) resulted in sig-
nifi cant PFS benefi t for intracranial disease, espe-
cially as fi rst line treatment and in asymptomatic 
CNS melanoma metastases. Therefore, systemic 
therapy as initial treatment for patients with as-
ymptomatic CNS melanoma metastases is an im-
portant new option for the patients and is even 
considered practice changing.
Unfortunately, mucosal, and even more so, 
uveal melanoma, represent diff erent entities, with 
limited effi  cacy of immunotherapy in mucosal 
melanoma (17), and basically no eff ect in uveal 
melanoma.
ONCOLYTIC VACCINES
Oncolytic vaccine, so called talimogen – la-
herparepvec (T-VEC) has been approved in local, 
intralesional treatment of patients with unresect-
able cutaneous, subcutaneous and/or palpable or 
ultrasonographically detectable lymph node me-
tastases. It is an att enuated herpes-symplex virus 
type I, programmed to be replicated within tumor 
and to produce GM-CSF. Durable response rates 
(DRR), were signifi cantly higher in patients re-
ceiving T-VEC compared to GM-CSF, as was over-
all response rate, with 10.8% of complete respons-
es, and with median of response of 8.2 months. 
Median OS was not signifi cantly diff erent, but at 
the borderline of statistical signifi cance (23.3 vs 
18.9 months, HR 0.79, P=0.051). With the use of 
this type of immunotherapy, certain so called ab-
scopal eff ect was noticed, i.e. antitumor eff ect in 
non-injected metastatic lesions and in visceral 
metastatic sites (18).
T-VEC is currently investigated in clinical tri-
als with various systemic therapies in metastatic 
melanoma patients.
ADOPTIVE IMMUNOTHERAPY
Various types of adoptive immunotherapy in 
highly selected patients have, according to some 
studies, yielded considerate and long-term thera-
peutic responses, but additional randomized clin-
ical studies conducted on larger number of pa-
tients are needed.
OTHER CYTOKINES AND VACCINES
In metastatic melanoma treatment, other 
 cytokines, as well as tumour vaccines have been 
investigated.
Immunotherapy in adjuvant melanoma treatment
Clinical studies ECOG 1684 (19) and Inter-
group E1694 (20), as well as meta – analysis of 
various studies (21), have shown effi  cacy of high 
dose interferon – alpha (IFN-alpha) in adjuvant 
treatment of high risk melanoma patients.
Interferon – alpha is the most effi  cient in high 
doses, that are also the most toxic ones, although 
in some countries, intermediate, even low IFN – 
alpha doses are used (latt er particularly in Ger-
many). Pegilated interferon has, in EORTC 18991 
study (22) shown benefi t in adjuvant treatment in 
two subgroups of patients, those with lymph node 
micrometastases (but not in lymph node macro-
metastases), and those with ulcerated melanomas 
(unlike non – ulcerated).
In USA, based of results of EORTC 18071 
study (23) high doses of ipilimumab have been re-
cently registered in adjuvant treatment of high risk 
melanoma patients with stage III disease (10 mg/kg 
every three weeks for four applications, then addi-
tional applications every 12 weeks until three years 
of therapy in total). In this phase III study, patients 
(N=951) have been randomized to receive either 
ipilimumab or placebo. Patients receiving ipilim-
umab had signifi cantly longer relaps-free survival 
(RFS) – 5-year - RFS 40.8% vs 30.3%, HR 0.76, with 
signifi cantly longer distant metastasis – free sur-
vival (DMFS); 5-year – DMFS 48.3% vs 38.9%, HR 
0.76, and signifi cantly longer OS; 5-year OS 65.4% 
vs 54.4%, HR 0.72, P=0.001. However, this benefi t 
has been achieved at the cost of high toxicity (98.7% 
of patients receiving ipilimumab had some sort of 
toxicity, and even 54.1% had adverse events of 
grade 3 or 4, that, in fi ve patients resulted in treat-
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ment-related death), and reduced life quality, that, 
however, according to study results, did not reach 
statistical signifi cance.
CheckMate-238, ongoing phase 3 study, pre-
sented at ESMO 2017 (24), showed that patients 
with stage IIIb/IIIc or stage IV melanoma at high 
risk of recurrence following complete surgical re-
section had greater recurrence-free survival (RFS) 
with adjuvant nivolumab compared to adjuvant 
high-dose ipilimumab. Stage IIIb, IIIc, and IV dis-
ease was reported for 34%, 47%, and 19% of pa-
tients, respectively. Thirty-two percent of patients 
had ulcerated primary disease, 48% had macro-
scopic lymph node involvement, and 42% of pa-
tients were positive for the BRAF mutation. RFS 
was signifi cantly improved with nivolumab over 
ipilimumab at a median follow-up of 18.5 months; 
the 18-month RFS rates were 66.4% versus 52.7%, 
respectively.
CONCLUSIONS
Various types of immunotherapy have been 
present for a long time in melanoma treatment, 
and contemporary types of immunotherapy, like 
pembrolizumab, nivolumab, ipilimumab, com-
bined therapy with nivolumab and ipilimumab, 
and T-VEC, have been established in recent years 
as the standard-of-care treatment for advanced-
stage melanoma.
Immunotherapy of metastatic melanoma 
also makes headway in research of new and prom-
ising types of immunotherapy due to high immu-
nogeneity of these tumours.
Several types of clinical studies in melanoma 
immunotherapy are currently ongoing – sequen-
tial studies that should, in BRAF V600-positive pa-
tients, answer the question regarding sequencing 
of targeted and immunotherapy, and concomitant 
studies that are combining immunotherapy and 
targeted therapy, or intralesional with systemic 
immunotherapy. Phase 1 clinical studies show 
promising antitumour activity of triplet regimens 
(immunotherapy with combined BRAF-inhibition 
and MEK-inhibition) in patients with BRAF-mu-
tant melanoma. Studies are also investigating new 
types of immunotherapy in metastatic melanoma 
treatment, e.g. anti-PD-L1 antibiodies and other 
checkpoint inhibitors, either separately or in dif-
ferent combinations. For instance, combinations 
of anti-PD-1 with IDO-1 inhibitors (25), or with 
anti-LAG-3 (26), seem to be well tolerated and 
showed promising clinical activity.
However, in this ongoing enthusiasm, great-
er scrutiny of the results of clinical trials exploring 
combination therapies is required, in order to en-
sure that synergistic therapeutic interactions are 
achieved without synergistic toxicity.
Also, studies of adjuvant use of PD-1 inhibi-
tors, either versus placebo, ipilimumab, or high 
dose IFN-alpha, are on the way, as well as study 
comparing adjuvant use of high dose ipilimumab, 
low dose ipilimumab, or high dose IFN-alpha.
Resistance mechanisms are being elucidated; 
eff ectiveness of therapy might be limited by loss 
of tumour antigen presentation and Tcell traffi  ck-
ing. Biomarkers of response should be further ex-
plored.
Substantial heterogeneity exists in the natu-
ral history of metastatic melanoma, including dif-
ferences in the pace of disease progression and the 
sites of metastatic lesions, as well as heterogeneity 
in patients’ characteristics; this should also be tak-
en into account in further clinical studies.
Some interesting investigations have emer-
ged recently, e.g. how diversity and composition 
of the gut microbiome infl uence response to anti-
PD-1 immune checkpoint therapy in patients with 
metastatic melanoma (27). Also, clinicans treating 
melanoma patients are nowadays paying more at-
tention to patients who would normally be ex-
cluded from clinical trials, such as elderly patients, 
or patients with autoimmune diseases, besides 
patients with CNS metastases, who have already 
been studied more closely, as mentioned earlier.
We anticipate that immunotherapy in mela-
noma treatment has not reached its peak, either as 
independent therapeutic option, or combined 
with other therapies, in metastatic, as well as in 
adjuvant, or neoadjuvant sett ing.
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